These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 11060831

  • 1. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C, Brendorp B, Køber L.
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2695-704. PubMed ID: 11060831
    [Abstract] [Full Text] [Related]

  • 2. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H, Saliba W.
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [Abstract] [Full Text] [Related]

  • 6. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN.
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE, Baquero GA, Nickolaus MJ, Wolbrette DL, Kelleman JJ, Samii S, Grando-Ting J, Penny-Peterson E, Davidson WR, Young SK, Naccarelli GV, Gonzalez MD.
    Congenit Heart Dis; 2014 Sep; 9(3):221-7. PubMed ID: 23947935
    [Abstract] [Full Text] [Related]

  • 12. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH, Pollak A, Singh SN, Friedrich T.
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP, Cox CD.
    Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
    [Abstract] [Full Text] [Related]

  • 16. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL, Hilleman DE.
    Pharmacotherapy; 2000 Jul; 20(7):776-86. PubMed ID: 10907968
    [Abstract] [Full Text] [Related]

  • 17. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.
    Køber L, Bloch Thomsen PE, Møller M, Torp-Pedersen C, Carlsen J, Sandøe E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ, Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group.
    Lancet; 2000 Dec 16; 356(9247):2052-8. PubMed ID: 11145491
    [Abstract] [Full Text] [Related]

  • 18. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH, Decara JM.
    Am Heart J; 2000 Nov 16; 140(5):697-706. PubMed ID: 11054613
    [Abstract] [Full Text] [Related]

  • 19. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
    Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, Santini M.
    Eur Heart J; 2000 Aug 16; 21(15):1265-73. PubMed ID: 10924317
    [Abstract] [Full Text] [Related]

  • 20. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.
    Nagra BS, Ledley GS, Kantharia BK.
    J Cardiovasc Pharmacol Ther; 2005 Sep 16; 10(3):191-5. PubMed ID: 16211208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.